Business Development Insulin Life Science 
Pharmaceutical Technology
DECEMBER 22, 2022
The company has partnered with life sciences-focused investors Sixth Street and Royalty Pharma with an aim to bring substantial non-dilutive, low-cost capital to boost innovation and growth. It was also announced that the organisation would enter into collaboration with the Juvenile Diabetes Research Foundation (JDRF).
XTalks
AUGUST 2, 2023
They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Merck’s total global revenue from Lagevrio was $5.68 billion in 2022. billion ($8.72 billion USD) in 2022.
Expert insights. Personalized for you.
130 
Let's personalize your content